On March 5, the government work report of the State Council reviewed and prospected the innovation and development of China’s industrial chain. In the past year, China has achieved remarkable results in a number of measures to strengthen innovation leadership and stabilize the industrial chain and supply chain. Promote the implementation of major science and technology projects by strengthening the construction of national laboratories. Reform and improve the management of scientific research funds of the central government, increase the proportion of indirect expenses, and expand the autonomy of scientific research. We will continue to implement the policy of adding and deducting R & D expenses, and increase the proportion of adding and deducting R & D expenses of manufacturing enterprises to 100%. Strengthen intellectual property protection. Carry out actions to strengthen and supplement the chain of key industries. The report concludes that the digital and intelligent transformation of traditional industries has accelerated, and emerging industries have maintained a good momentum of development.
The pharmaceutical and biological sector is an inseparable field with macro policies, and it is also the “bridgehead” of scientific and technological innovation in 2021. The wind direction of digitization, new models, new technologies and even capital converges, collides and integrates in this field, “butterfly change” has become a true portrayal of this sector. Among them, the innovation breakthrough of traditional leading pharmaceutical enterprises is particularly obvious.
As an established pharmaceutical enterprise on GEM, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) is responding to the call of the state and actively participating in the construction of national laboratories and other projects. Up to now, its subordinate research institutes cover two national technology platforms, CNAs certified laboratories and other authoritative scientific research and technology platforms, and won the title of “national advanced collective of professional and technical talents” jointly issued by four ministries and commissions in 2021, becoming a typical national advanced collective and the only comprehensive pharmaceutical enterprise on the list.
Based on scientific and technological research and development, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) deeply cultivates the development of the whole industrial chain, gradually improves the industrial chain, and brings together a group of pharmaceutical “little giants” to form a large health matrix across multiple sectors Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) the business model has also changed from the single line output of Xuebijing to the three arrows of finished drugs, traditional Chinese medicine formula particles and medical devices with Xuebijing as the core. Then, promote the layout of raw and auxiliary materials to the upstream and carry out the medical services of shangyiren family to the downstream. Coupled with the introduction of the intelligent supply chain model of medicine and equipment, the six carriages keep pace.
With the promotion of chain supplement, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) formed a strong industrial chain, and set off a new strategy of big health industry integration in early 2021 Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) chairman Yao Xiaoqing proposed the “digital red day” plan to launch digital reform in its six sectors: finished drugs, traditional Chinese medicine formula granules, raw and auxiliary materials, medical devices, medical and health services and intelligent supply chain of medical devices. It is planned to apply technologies such as intelligent production, big data, Internet and intelligent equipment to improve the efficiency of R & D, production and sales, realize the overall efficient coordination and rapid response of the sector, and reshape its core competitiveness in the market.
With profound scientific research accumulation and industrial transformation experience, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) ‘s great health innovation strategy has made remarkable achievements in 202130 Shenzhen Ruihe Construction Decoration Co.Ltd(002620) 21 performance express shows that with the rapid industrial expansion in the fields of traditional Chinese medicine formula granules, finished drugs and raw and auxiliary drugs, the attributable net profit was 688.3 million yuan, with a year-on-year increase of 20.03%, reaching the performance growth for three consecutive years.
With the accelerated innovation of Internet, big data, cloud computing, artificial intelligence, blockchain and other technologies, relevant data show that China’s digital economy accounts for 40% of GDP. Against this background, in view of the industrial development in 2022, the government work report pointed out the general direction of “deeply implementing the innovation driven development strategy and consolidating and strengthening the foundation of the real economy”, and put forward higher innovation requirements than last year.
The “healthy” matrix has been built in advance. Up to now, the industrial expansion of Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) in multiple sectors has started: the new thousand ton production capacity of formula granules in Gansu base is about to start; Innovation Medical Management Co.Ltd(002173) instruments such as respiratory rate oximeter and handheld electrocardiograph are planned to be put on the market; The production capacity of medicinal cellulose ether and high-end heparin API is expanded and ready to go; Speed up the listing process of generic drugs and innovative drugs in just needed categories such as cardio cerebrovascular and anti-tumor.
Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) the acceleration of innovation in 2022 is an epitome of the digital transformation in the pharmaceutical field. With the acceleration of industrial integration and the deepening of cooperation modes such as industry university research, enterprises with strong scientific research ability and industrial transformation ability will usher in more opportunities and become an important force in accelerating China’s innovation and development strategy.
